Open Orphan PLC GBP5.1m RSV contract (6028S)
November 17 2021 - 1:00AM
UK Regulatory
TIDMORPH
RNS Number : 6028S
Open Orphan PLC
17 November 2021
17 November 2021
Open Orphan plc
("Open Orphan" or the "Company")
GBP5.1m RSV Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in vaccine
and antiviral testing using human challenge clinical trials ,
announces that hVIVO , a subsidiary of Open Orphan, has signed a
GBP5.1m contract with a biopharmaceutical company to test its
Investigational Medicinal Product (IMP) using hVIVO's respiratory
syncytial virus (RSV) Human Challenge Study Model.
The study is due to commence in H2 2022, with the revenue from
the contract being recognised across 2021 and 2022. hVIVO will
conduct this study on behalf of this biopharmaceutical client to
demonstrate the efficacy of its IMP against RSV infection.
RSV is a contagious virus that affects the respiratory tract of
children and at-risk older adults; in severe cases, it can cause
pneumonia and other life-threatening breathing difficulties. RSV is
a significant public health threat and is one of the leading causes
of hospitalisation of young children across the world. It also
poses a significant threat to at-risk older adults; in the current
climate, RSV may also lower immunity and increase the risk of
developing COVID-19, and where these infections occur together, it
can worsen the severity of COVID-19 illness.
hVIVO has two decades of experience and expertise in safely
conducting challenge studies across a range of respiratory viruses,
including RSV, various strains of Influenza, human Rhinovirus HRV
(common cold virus), malaria, and asthma. In October 2020, this
expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan said: "We are
pleased to have signed this contract to test our client's product
using our RSV Human Challenge Study Model. It is testament to our
position as the world leading provider of Phase IIa human challenge
study clinical trials that innovative biopharmaceutical companies,
as well as Big Pharma, are actively and regularly engaging us to
test their novel vaccine and antiviral candidates.
"RSV is one of several infectious and respiratory disease areas
of unmet need that we are seeing rapidly growing interest in from
drug developers. We look forward to working with more companies
across the world to test their antivirals and vaccines, as Phase
IIa human challenge studies increasingly become part of mainstream
clinical trial design."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 (as implemented into
English law) ("MAR"). With the publication of this announcement via
a Regulatory Information Service, this inside information is now
considered to be in the public domain.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
Individuals interested in taking part in COVID-19 human
challenge study research can learn more at www.UKCovidChallenge.com
.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR +44 (0)20 7933 8780 or openorphan@walbrookpr.com
& IR)
Paul McManus/ Sam Allen/ Louis Ashe-Jepson +44 (0)7980 541 893/ +44 (0) 7502 558
258 / +44 (0) 7747 515393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. Open Orphan has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of other models. There has been
an explosion in the growth of the infectious disease
pharmaceuticals market, which is estimated to grow to in excess of
$250bn by 2025. The Group is focused on refreshing its existing
challenge models and develop new models, such as Malaria, to
address the dramatic growth potential of the global infectious
disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFEFUMEFSEIF
(END) Dow Jones Newswires
November 17, 2021 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024